MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49: 12-9.
Häuser W, Finn DP, Kalso E, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018;22(9): 1547-64.
Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4): 327-60.
Bouquié R, Deslandes G, Mazaré H, et al. Cannabis and anticancer drugs: societal usage and expected pharmacological interactions – a review. Fundam Clin Pharmacol. 2018;32(5): 462-84.
Santé Canada. Renseignements destinés aux professionnels de la santé Le cannabis (marihuana, marijuana) et les cannabinoïdes. Santé Canada; octobre 2018. ISBN: 978-0-660-27828-5.
Nielsen S, Sabioni P, Trigo JM, et al. Opioid-sparing effect of cannabinoids: a systematic review and meta-analysis. Neuropsychopharmacology. 2017;42: 1752–65.
Lucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. Int J Drug Policy. 2017;42: 30-5.
Lucas P, Baron EP, Jikomes N. Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients. Harm Reduct J. 2019;16(1): 9.
Baron EP, Lucas P, Eades J, Hogue O. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. J Headache Pain. 2018;19(1): 37.
Obradovic I, pour l‘Observatoire Français des Drogues et des Toxicomanies. La réponse pénale à la conduite sous influence (alcool et stupéfiants). Tendencies. 2013;91: 1-6.